Third line H. pylori eradication therapy with sitafloxacin, amoxicillin and vonapraza

Not Applicable

• Conditions: Helicobacter pylori infection; A498

• Registration Number: JPRN-jRCTs031180413
• Lead Sponsor: Hirata Kenro

Brief Summary

Sitafloxacin-amoxicillin-vonaprazan 7day regimen was effective and safe as a third- or later-line H. pylori eradication regimen.

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2019-03-22
• Study Completion: 2022-12-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 75

Inclusion Criteria

H. pylori-positve patients after the 2nd line H. pylori eradication therapy with informed consent.

Exclusion Criteria

1. Patients with allergy for quinolones
2. Patients with allergy for PPIs
3. Patients with severe liver injury and/or severe renal damage
4. Pregnancy or possible pregnancy
5. Patients who were recognized as inappropriate for entry

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The efficacy of eradication treatment

Secondary Outcome Measures

Name	Time	Method
1) adverse events <br>2) MIC of STFX,AMPC, gyaA mutation